Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Staar Surgical stock surged nearly 8% after Stifel analyst Thomas Stephan upgraded the company to 'buy' from 'hold' and raised the price target to $31 from $28. The upgrade was driven by expectations of higher sales in the second half of 2026, particularly for the company's surgically implanted lenses in China, and recognition of Staar's potential as an acquisition target and product developer.